Skip to main content

Urine Studies

Urine studies — urinalysis, urine culture, urine cytology, prostatitis-localization tests, 24-hour collections, and emerging expanded-culture / next-generation-sequencing methods — are the workhorse laboratory tests of functional and reconstructive urology and urogynecology. Their value is entirely context-dependent: the colony-count threshold that confirms a UTI in a healthy outpatient woman is meaningless in a neobladder; the same positive dipstick that prompts a hematuria evaluation in one patient is part of the expected baseline in another. The reconstructive surgeon's job is less about ordering the right test than about interpreting it in the right population — diversion patients, augmented bladders, CIC users, post-prostatectomy men, post-mid-urethral-sling women, men with chronic prostatitis-pelvic-pain syndromes, and stone formers each have their own thresholds and pitfalls.[1][2][3]

Specimen Collection​

Proper specimen collection is foundational; downstream interpretation cannot rescue a contaminated or mishandled specimen.[1][2]

  • Midstream clean-catch is the standard for voided specimens. Skin cleansing is generally recommended despite some evidence that it does not reduce contamination in women.[1][2]
  • Straight (in-and-out) catheterization provides a less contaminated specimen and is preferred when voided specimens are unreliable or when lower colony-count thresholds are clinically important (e.g., suspected UTI in a patient who cannot reliably collect midstream).[1]
  • Indwelling catheter specimens are problematic due to rapid biofilm formation; culture from a long-dwelling catheter is strongly discouraged. If required, sample from the port of a newly inserted device.[1]
  • Specimens from urinary diversions (ileal conduits, nephrostomies) are discouraged for routine UTI diagnosis because of universal chronic colonization (see diversion section below).[1]
  • Suprapubic aspiration is the most reliable; routinely cultured to detect bacteria as low as 1,000 CFU/mL, and counts as low as 200 CFU/mL may be significant.[1]
  • Transport: urine should not remain at room temperature >30 minutes. Boric-acid preservative tubes or refrigeration if processing is delayed; specimens held at room temperature >4 hours show misleading overgrowth.[1]
  • Epithelial cells on microscopy suggest skin contamination — repeat with instructed midstream or catheterized collection.[3]

Dipstick Urinalysis​

Dipstick provides rapid screening but must be interpreted in clinical context.[4][5]

  • Leukocyte esterase (LE) — produced by neutrophils; indicates inflammation or infection. Sensitivity for UTI is moderate (~71% in culture-confirmed UTI). Positive in non-infectious inflammation (interstitial cystitis, stones, incontinence). Pyuria is common in older adults with LUTS even without infection.[5][6]
  • Nitrites — more specific for infection (produced by nitrate-reducing gram-negatives such as E. coli). Sensitivity is poor with frequent voiding (short bladder incubation), and with Enterococcus or Pseudomonas (which do not reduce nitrates).[3][4][5]
  • Hematuria — a positive dipstick must be confirmed by microscopy of the sediment. Dipstick alone does not define microhematuria; false positives occur with hemoglobinuria, myoglobinuria, and dilute urine.[7][8]
  • pH — relevant for stone disease. Persistently low pH suggests uric-acid stones; high pH suggests struvite or distal renal tubular acidosis.[4][9]
  • Protein — trace proteinuria may be benign; ≥1+ warrants quantitative testing (spot albumin/creatinine ratio).[4]

Microscopic Urinalysis​

Microscopy is more sensitive than dipstick and is essential for confirming and characterizing findings.[3][4][7]

  • Red blood cells — ≥3 RBCs/HPF on microscopic examination of spun sediment defines microhematuria per the AUA. Dysmorphic RBCs and RBC casts suggest a glomerular (upper-tract) source; isomorphic RBCs suggest a lower-urinary-tract origin.[7][8][10][11]
  • White blood cells — pyuria (>5–10 WBCs/HPF) supports infection but is nonspecific. Absence of pyuria has a negative predictive value >95% for ruling out UTI.[6]
  • Bacteria — bacteria seen in unspun urine support UTI.[7]
  • Crystals — pathognomonic morphologies direct the stone workup: hexagonal = cystinuria, coffin-lid = struvite, envelope-shaped = calcium oxalate.[12][13]
  • Casts — RBC casts indicate glomerulonephritis; WBC casts suggest pyelonephritis or interstitial nephritis.

Urine Culture: Thresholds and Interpretation​

Culture thresholds vary by collection method and clinical context.[1][6][14]

Collection MethodDiagnostic ThresholdNotes
Midstream voided (women)≥10⁵ CFU/mL standard; ≥10² CFU/mL may be significant if symptomaticTwo consecutive specimens preferred for ASB diagnosis
Midstream voided (men)≥10⁵ CFU/mL; ≥10³ CFU/mL may indicate infectionSingle specimen sufficient for ASB diagnosis
Straight catheterization≥10³ CFU/mLLess contamination; lower threshold appropriate
Indwelling catheter≥10³ CFU/mL (IDSA); ≥10⁵ CFU/mL (CDC)Symptoms required; biofilm colonization confounds
Suprapubic aspirationAny growth (≥10² CFU/mL) may be significantGold standard; minimal contamination
Cystoscopy-obtained≥10³ CFU/mL routinely; lower thresholds may be significantDiscuss with lab in advance

Key interpretive principles:

  • ≥3 species in a specimen usually indicates contamination.[1]
  • Polymicrobial cultures may be clinically significant in patients with stents, stones, diversions, or recurrent UTI.[1]
  • Urine culture should not be performed without accompanying microscopy because of the high rate of contamination and colonization.[3]

Meares-Stamey Localization (Chronic Bacterial Prostatitis)​

For chronic bacterial prostatitis, the Meares-Stamey 4-glass test remains the diagnostic standard, although it is cumbersome and rarely performed in contemporary practice.[1][15][16]

  • VB1 — first-voided urine (urethral flora)
  • VB2 — midstream urine (bladder urine)
  • EPS — expressed prostatic secretions after prostatic massage
  • VB3 — post-massage voided urine (prostatic fluid)

Chronic bacterial prostatitis is diagnosed when the bacterial colony count in EPS or VB3 exceeds VB2 by ≥10-fold.[15][17] The modified 2-glass test (VB2 vs VB3 only) has sensitivity 44–54%, specificity 100%, and accuracy 96–98%, making it the practical alternative used most commonly today.[15][17] Prostate massage is contraindicated in acute bacterial prostatitis because of the bacteremia risk.[1][16]

Hematuria Workup​

Per the AUA/SUFU 2025 microhematuria guideline, evaluation is risk-stratified.[10][18][19]

  • Microhematuria is defined as ≥3 RBCs/HPF on microscopic examination — not on dipstick alone. A positive dipstick must be confirmed microscopically.[8][10][19]
  • Gross hematuria always warrants urgent urologic evaluation with cystoscopy and upper-tract imaging given the ~16.5% bladder-cancer risk.[18][19]
  • Urine cytology is not recommended for initial hematuria evaluation. It may be considered in high-risk patients with equivocal cystoscopic findings, persistent microhematuria with irritative voiding symptoms, or risk factors for carcinoma in situ — sensitivity for high-risk bladder cancers is ~58%.[10][19]
  • Evaluation should proceed even on anticoagulant or antiplatelet therapy.[19]

Bladder-Cancer Surveillance (Cytology)​

For the reconstructive urologist, urine cytology is most relevant after cystectomy + diversion and during NMIBC surveillance, per NCCN.[20]

  • Intermediate-risk NMIBC — cytology at 3, 6, and 12 months in year 1, then every 6 months in year 2, then annually.
  • High-risk NMIBC — cytology every 3 months in year 1, every 6 months in years 2–5, then annually.
  • Post-cystectomy — consider urine cytology and urethral wash cytology every 6–12 months for the first 2 years, especially with high-risk features (positive urethral margin, multifocal CIS, prostatic urethral invasion).
  • There is no routine role for cytology or urinary biomarkers in low-risk NMIBC.

Cytology performance in diverted patients. Interpretation in patients after radical cystectomy with urinary diversion is genuinely tricky because diverted-patient specimens are full of degenerated epithelial cells, histiocytes, bacteria, and cellular debris. Despite this, urine cytology in this population demonstrates sensitivity 82%, specificity 97%, PPV 75%, and NPV 98% for detecting remnant urothelial recurrence — the high NPV is the practical value, since a negative cytology is reassuring.[36] FISH (UroVysion) in the same setting performs at sensitivity 85.7%, specificity 86.5%, but PPV only 23.1%;[37] like cytology, its primary clinical utility is its negative predictive ability. Sensitivity for high-grade tumors and CIS is ~82% with specificity >90%, while low-grade tumors remain difficult to distinguish from reactive changes.

Urinary Stone Disease: Urinalysis and 24-Hour Urine​

Urinalysis is part of the initial screening evaluation for all stone formers.[9]

  • Dipstick and microscopy assess pH (low → uric acid; high → struvite/infection), hematuria, pyuria (concurrent infection), and crystals pathognomonic of stone type.[9][12]
  • Urine culture is obtained when urinalysis suggests UTI or in patients with recurrent UTIs — struvite stones are infection-driven.[9]
  • 24-hour urine collection is the mainstay of metabolic evaluation for high-risk or recurrent stone formers. The AUA recommends one or two collections on a random diet, analyzed for volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine. Dominance analysis identifies calcium, volume, and citrate as the most important urinary factors for stone risk.[9][21] Real-world adherence is poor even where the indication is clearest: in a large primary-care database, only 4.8% of stone patients underwent 24-hour urine testing and 0.6% had all three target measurements (calcium, oxalate, citrate); testing rates increased nearly sixfold after nephrology consultation (OR 6.09) vs urology visits (OR 1.95).[38]
  • Screen for primary hyperparathyroidism in recurrent stone formers — PHPT is present in 3–5% of stone formers, and serum intact PTH should be obtained whenever serum calcium is high or high-normal. Critically, thiazide diuretics — commonly prescribed for hypercalciuria — should not be started in patients with undiagnosed PHPT, because they can unmask hypercalcemia.[39]

Urinary Diversions and Augmented Bladders​

Urinalysis and culture interpretation is fundamentally altered in patients with bowel-based reconstructions — this is one of the highest-yield reframings in reconstructive urology.[22][23][24]

  • Positive urinalysis is universal. By 12 months post-cystectomy, virtually 100% of patients with ileal conduits or neobladders have positive dipstick for leukocyte esterase, hemoglobin, and bacteria on microscopy.[22]
  • All urine cultures are positive by 12 months, with polymicrobial results more common in neobladders (81%) than conduits (67%).[22]
  • Bacteriuria should not be treated in the absence of systemic symptoms. The simple fact of a positive urinalysis or culture does not warrant antimicrobials.[22][23]
  • Hydronephrosis is independently associated with infectious complications (OR 4.2) and should prompt evaluation.[22]
  • Long-term prophylactic antibiotics are ineffective in preventing bacteriuria in diverted patients.[23]
  • Patients with bowel-based reconstructions require lifelong surveillance including annual history, exam, basic metabolic panel, and urinary-tract imaging.[24]

Neurogenic Bladder and Clean Intermittent Catheterization​

CIC patients present unique diagnostic challenges.[6][14][25]

  • Specimens obtained via CIC are collected directly from the bladder and are less contaminated than voided specimens.[6]
  • The IDSA defines catheter-associated UTI as ≥10³ CFU/mL of ≥1 bacterial species from a catheterized specimen with compatible symptoms.[14]
  • ASB is extremely common in CIC patients and should not be screened for or treated — treatment does not improve outcomes and promotes resistance.[14][26][27]
  • The AUA/SUFU NLUTD guideline recommends UA + culture only when signs/symptoms suggest UTI, with culture-directed antibiotics given the higher resistance rates.[25]

Perioperative Urine Testing​

The AUA Best Practice Statement provides a tiered approach.[3]

  • All urologic procedures — evaluate for UTI symptoms with dipstick, microscopy, and/or culture, scaled to procedural risk.[3]
  • Endoscopic procedures with mucosal trauma — screen and treat ASB. Together with pregnancy, this is one of only two populations where the IDSA recommends ASB treatment.[3][14][26]
  • Prosthetic device implantation (artificial urinary sphincter, penile prosthesis) — routine preoperative urine culture is of questionable efficacy: prosthetic infections are typically caused by biofilm-producing skin flora, not urinary pathogens. A retrospective study of 721 AUS / penile-prosthesis cases found no difference in device-infection rates between patients with and without preoperative bacteriuria (3% vs 4.3%).[14]
  • Mid-urethral sling — preoperative culture screening in asymptomatic women does not reduce postoperative UTI rates. Independent risk factors for post-sling UTI include smoking, history of recurrent UTI, and need for postoperative self-catheterization (OR 8.75). Postoperative prophylactic nitrofurantoin has not been shown to reduce UTI/bacteriuria.[28][29]
  • Elective procedures should be deferred during active symptomatic UTI until treatment is complete and symptoms resolve.[3]

Recurrent UTI in Women (Urogynecologic Perspective)​

Recurrent UTI (≥2 in 6 months or ≥3 in 12 months) requires at least one culture-confirmed episode.[30][31][32]

  • Urine culture is the gold standard. In symptomatic women, growth as low as 10² CFU/mL may reflect true infection.[5]
  • Dipstick has moderate utility — a negative dipstick does not rule out UTI in patients with high pretest probability.[5]
  • AUA/CUA/SUFU guidance emphasizes obtaining culture and limiting cystoscopy and upper-tract imaging to women with additional risk factors.[31][32]
  • ASB is common in older women (>15%, up to 50% in long-term care) and should not be treated.[26][27]

Expanded Quantitative Urine Culture (EQUC) and Emerging Technologies​

Standard urine culture (SUC) misses a significant proportion of uropathogens. EQUC uses larger urine volumes and diverse culture conditions (multiple agars, CO₂ incubation, 48-hour growth) and detects 67% more uropathogens than SUC overall.[33] A streamlined EQUC protocol (100 µL on BAP, CNA, and MacConkey agars in 5% CO₂ for 48 hours) achieves 84% uropathogen detection vs 33% with SUC.[33]

The IDSA / ASM 2024 microbiology guideline notes that while EQUC can recover additional pathogens in lower quantities, clinical relevance has not been fully established and routine use is not supported for all populations.[1] EQUC is most useful in patients with chronic / persistent LUTS, recurrent UTI with negative SUC, and urinary incontinence.[34][35] Next-generation sequencing of urine is in development but not yet FDA-approved for UTI diagnosis, and there is concern about overtreatment.[1]

Asymptomatic Bacteriuria: When to Screen and Treat​

Per the 2019 IDSA guideline, screening and treatment of ASB is recommended only in:[14][26][27]

  • Pregnant women (first-trimester screening)
  • Patients undergoing endoscopic urologic procedures with anticipated mucosal trauma

Treatment is not recommended in older adults, diabetic patients, spinal-cord-injury patients, indwelling-catheter patients, non-urologic surgery, or non-renal solid-organ transplant recipients.[14][26][27]

Key Takeaways​

  • The AUA microhematuria definition is ≥3 RBCs/HPF on microscopy — never on dipstick alone.
  • ≥3 species in a culture is contamination unless the patient has stents / stones / diversion / recurrent UTI.
  • Urine cultures are universally positive by 12 months in diverted patients — bacteriuria alone is not an indication for antibiotics; treat only with systemic symptoms.
  • Routine preoperative culture screening does not reduce infection rates for prosthetic implantation (AUS, penile prosthesis) or mid-urethral sling.
  • ASB treatment is recommended only for pregnancy and endoscopic procedures with mucosal trauma.
  • The modified 2-glass Meares-Stamey test (VB2 vs VB3) is the practical contemporary alternative to the 4-glass test, with 96–98% accuracy.

See Also​

References​

1. Miller JM, Binnicker MJ, Campbell S, et al. "Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)." Clinical Infectious Diseases. 2024;ciae104. doi:10.1093/cid/ciae104

2. LaRocco MT, Franek J, Leibach EK, et al. "Effectiveness of Preanalytic Practices on Contamination and Diagnostic Accuracy of Urine Cultures: A Laboratory Medicine Best Practices Systematic Review and Meta-Analysis." Clinical Microbiology Reviews. 2016;29(1):105–47. doi:10.1128/CMR.00030-15

3. Lightner DJ, Wymer K, Sanchez J, Kavoussi L. "Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis." Journal of Urology. 2020;203(2):351–356. doi:10.1097/JU.0000000000000509

4. Hitzeman N, Greer D, Carpio E. "Office-Based Urinalysis: A Comprehensive Review." American Family Physician. 2022;106(1):27–35B.

5. Chu CM, Lowder JL. "Diagnosis and Treatment of Urinary Tract Infections across Age Groups." American Journal of Obstetrics and Gynecology. 2018;219(1):40–51. doi:10.1016/j.ajog.2017.12.231

6. Schaeffer AJ, Nicolle LE. "Urinary Tract Infections in Older Men." New England Journal of Medicine. 2016;374(6):562–71. doi:10.1056/NEJMcp1503950

7. Ingelfinger JR. "Hematuria in Adults." New England Journal of Medicine. 2021;385(2):153–163. doi:10.1056/NEJMra1604481

8. Chapman JR, Geissler EK, Pomfret EA, et al. "2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors." KDIGO. 2017.

9. Pearle MS, Goldfarb DS, Assimos DG, et al. "Medical Management of Kidney Stones: AUA Guideline." Journal of Urology. 2014;192(2):316–24. doi:10.1016/j.juro.2014.05.006

10. Barocas DA, Lotan Y, Matulewicz RS, et al. "Updates to Microhematuria: AUA/SUFU Guideline (2025)." Journal of Urology. 2025;213(5):547–557. doi:10.1097/JU.0000000000004490

11. ACOG Practice Bulletin No. 155: "Urinary Incontinence in Women." Obstetrics and Gynecology. 2015;126(5):e66–e81. doi:10.1097/AOG.0000000000001148

12. Hernandez JD, Ellison JS, Lendvay TS. "Current Trends, Evaluation, and Management of Pediatric Nephrolithiasis." JAMA Pediatrics. 2015;169(10):964–70. doi:10.1001/jamapediatrics.2015.1419

13. Coe FL, Parks JH, Asplin JR. "The Pathogenesis and Treatment of Kidney Stones." New England Journal of Medicine. 1992;327(16):1141–52. doi:10.1056/NEJM199210153271607

14. Nicolle LE, Gupta K, Bradley SF, et al. "Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America." Clinical Infectious Diseases. 2019;68(10):e83–e110. doi:10.1093/cid/ciy1121

15. Lam JC, Stokes W. "Acute and Chronic Prostatitis." American Family Physician. 2024;110(1):45–51.

16. Kulkarni PA, Cortés-Penfield NW, Brehm TJ, et al. "State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis." Clinical Infectious Diseases. 2026;82(1):1–13. doi:10.1093/cid/ciaf483

17. Borgert BJ, Wallen EM, Pham MN. "Prostatitis." JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

18. Lenis AT, Lec PM, Chamie K, Mshs MD. "Bladder Cancer: A Review." JAMA. 2020;324(19):1980–1991. doi:10.1001/jama.2020.17598

19. Nielsen M, Qaseem A. "Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians." Annals of Internal Medicine. 2016;164(7):488–97. doi:10.7326/M15-1496

20. National Comprehensive Cancer Network. "Bladder Cancer (NCCN Guidelines)." Updated 2026-03-16.

21. Ferraro PM, Taylor EN, Curhan GC. "24-Hour Urinary Chemistries and Kidney Stone Risk." American Journal of Kidney Diseases. 2024;84(2):164–169. doi:10.1053/j.ajkd.2024.02.010

22. Magistro G, Zimmermann L, Bischoff R, et al. "The Natural Course of Urinalysis After Urinary Diversion." World Journal of Urology. 2021;39(5):1559–1567. doi:10.1007/s00345-020-03355-0

23. Qu LG, Adam A, Ranasinghe W, Lawrentschuk N. "Systematic Review: Bacterial Colonisation of Conduits and Neobladders — When to Test, Watch, and Treat." World Journal of Urology. 2020;38(6):1413–1422. doi:10.1007/s00345-019-02964-8

24. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-Up." Journal of Urology. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

25. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Diagnosis and Evaluation." Journal of Urology. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

26. Luu T, Albarillo FS. "Asymptomatic Bacteriuria: Prevalence, Diagnosis, Management, and Current Antimicrobial Stewardship Implementations." American Journal of Medicine. 2022;135(8):e236–e244. doi:10.1016/j.amjmed.2022.03.015

27. Colgan R, Jaffe GA, Nicolle LE. "Asymptomatic Bacteriuria." American Family Physician. 2020;102(2):99–104.

28. Laus K, Eng S, Nguyen JN. "Impact of Preoperative Urinary Tract Infection Screening in Asymptomatic Women Undergoing Midurethral Sling." International Urogynecology Journal. 2024;35(2):423–430. doi:10.1007/s00192-023-05716-w

29. Sanaee MS, Hutcheon JA, Larouche M, et al. "Urinary Tract Infection Prevention After Midurethral Slings in Pelvic Floor Reconstructive Surgery: A Systematic Review and Meta-Analysis." Acta Obstetricia et Gynecologica Scandinavica. 2019;98(12):1514–1522. doi:10.1111/aogs.13661

30. Advani SD, Thaden JT, Perez R, et al. "State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women." Clinical Infectious Diseases. 2025;80(3):e31–e42. doi:10.1093/cid/ciae653

31. Kwok M, McGeorge S, Mayer-Coverdale J, et al. "Guideline of Guidelines: Management of Recurrent Urinary Tract Infections in Women." BJU International. 2022;130 Suppl 3:11–22. doi:10.1111/bju.15756

32. Anger JT, Bixler BR, Holmes RS, et al. "Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline." Journal of Urology. 2022;208(3):536–541. doi:10.1097/JU.0000000000002860

33. Price TK, Dune T, Hilt EE, et al. "The Clinical Urine Culture: Enhanced Techniques Improve Detection of Clinically Relevant Microorganisms." Journal of Clinical Microbiology. 2016;54(5):1216–22. doi:10.1128/JCM.00044-16

34. Gasiorek M, Hsieh MH, Forster CS. "Utility of DNA Next-Generation Sequencing and Expanded Quantitative Urine Culture in Diagnosis and Management of Chronic or Persistent Lower Urinary Tract Symptoms." Journal of Clinical Microbiology. 2019;58(1):e00204-19. doi:10.1128/JCM.00204-19

35. Deen NS, Ahmed A, Tasnim NT, Khan N. "Clinical Relevance of Expanded Quantitative Urine Culture in Health and Disease." Frontiers in Cellular and Infection Microbiology. 2023;13:1210161. doi:10.3389/fcimb.2023.1210161

36. Chen H, et al. "Urine Cytology in Monitoring Recurrence in Urothelial Carcinoma After Radical Cystectomy and Urinary Diversion." Cancer Cytopathology. 2016;124(4):273–8. doi:10.1002/cncy.21650

37. Fernández MI, et al. "The Role of FISH and Cytology in Upper Urinary Tract Surveillance After Radical Cystectomy for Bladder Cancer." Urologic Oncology. 2012;30(6):821–4. doi:10.1016/j.urolonc.2010.08.006

38. Ferraro PM, Spasiano A, Gambaro G, et al. "24-H Urine Test Application in Patients With Kidney Stone Disease: A Population-Based Study in a Primary Care Setting." Journal of Nephrology. 2025. doi:10.1007/s40620-025-02389-0

39. Lui MS, Fisher JC, Underwood HJ, Patel KN, Ogilvie JB. "Stones Left Unturned: Missed Opportunities to Diagnose Primary Hyperparathyroidism in Patients With Nephrolithiasis." Surgery. 2022;171(1):23–28. doi:10.1016/j.surg.2021.03.073